X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dynamic polarization | The principle that information within a neuron flows in a predictable and consistent direction. | ILX:0103622 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dynamin | A family of high molecular weight GTP phosphohydrolases that play a direct role in vesicle transport. They associate with microtubule bundles (microtubules) and are believed to produce mechanical force via a process linked to GTP hydrolysis (MSH). | ILX:0103623 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dynorphin | ILX:0103624 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dynorphin A | ILX:0103625 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dyphylline | A theophylline derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis. (PubChem) Pharmacology: Dyphylline, a xanthine derivative, is a bronchodilator used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Dyphylline is a xanthine derivative with pharmacologic actions similar to theophylline and other members of this class of drugs. Its primary action is that of bronchodilation, but it also exhibits peripheral vasodilatory and other smooth muscle relaxant activity to a lesser degree. Mechanism of action: The bronchodilatory action of dyphylline, as with other xanthines, is thought to be mediated through competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of bronchial smooth muscle. Drug type: Approved. Small Molecule. Drug category: Bronchodilator Agents. Phosphodiesterase Inhibitors. Respiratory Smooth Muscle Relaxants. Vasodilator Agents | ILX:0103626 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dysgranular cortex | ILX:0103627 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dyskinesia | Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES (MeSH). | ILX:0103628 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dysmetria | Error in the range and force of movement | ILX:0103629 | 5 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dysplastic | ILX:0103630 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Dysthymic Disorder | Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self esteem, poor concentration or difficulty making decisions, and feelings of hopelessness (MeSH). | ILX:0103631 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dystonia | A persistent attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS (MeSH). | ILX:0103632 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dystonicity | A structural quality inhering in a bearer by virtue of its impaired elastic tension that facilitate a response to stimuli. | ILX:0103633 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dystrophic | A size quality inhering in a bearer by virtue of being abnormally developed, usually due to malnutrition. | ILX:0103634 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Dystrophin | A protein that is a translation product of the DMD gene or a 1:1 ortholog thereof. (PRO) It is a 427-kDa cytoskeletal protein that is a member of the family of ?-spectrin/?-actinin proteins that are characterized by an NH2-terminal actin-binding domain followed by a variable number of repeating units known as spectrin-like repeats. Mutations in the DMD gene are involved in Duchenne's Muscular Dystrophy. | ILX:0103635 | 4 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| E-1 neuron | Neuron associated with the anterior crossvein campaniform sensillum neuron, but does not possess a typical dendrite whose conspicuous distal tip can be seen near the surface of the epithelium (Murray et al., 1984). | ILX:0103636 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| E3 ubiquitin ligase SFC complex Skp1 subunit | A protein with a core domain composition consisting of an N-terminal Skp1 family, tetramerisation domain (PF03931) followed by a Skp1 family, dimerisation domain (PF01466). Skp1 proteins bind several F-box-containing proteins, and are involved in the ubiquitin protein degradation pathway. (PRO:CNA) | ILX:0103637 | 7 | scicrunch | 10/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| E46K Alpha-Synuclein Drosophila | These transgenic flies express human E46K mutant alpha-synuclein. This mutation increases the rate of alpha-synuclein aggregation. Its shape becomes more helical and there is enhanced contact between the C-terminal and the N-terminal. This model is used to study Parkinson's disease in the laboratory. | ILX:0103638 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| EAAT1 | ILX:0103639 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| EAAT2 | ILX:0103640 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| EAAT3 | ILX:0103641 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X